Evaluating biomarkers for coronary heart disease prognosis
A Prospective Longitudinal Multi-Omics Cohort of Patients With Coronary Heart Disease Undergoing Coronary Angiography
Shandong First Medical University · NCT05699629
This study is trying to find out which blood and stool markers can help predict health outcomes for people with coronary heart disease over two years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shandong First Medical University (other) |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05699629 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit patients diagnosed with coronary heart disease who are undergoing coronary angiography and follow them for at least two years. The study will track the incidence of major adverse cardiovascular events (MACE), including mortality and rehospitalization, while collecting blood and fecal samples for analysis. Additionally, it will gather comprehensive data on patients' socio-demographic factors, lifestyle, and medical history to investigate biomarkers and factors contributing to poor prognosis in coronary heart disease through multi-omics analysis.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with coronary heart disease or those experiencing unexplained chest pain requiring coronary angiography.
Not a fit: Patients with malignant tumors, infectious diseases, advanced liver diseases, or those unwilling to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools for patients with coronary heart disease, enhancing their management and outcomes.
How similar studies have performed: Other studies have shown success in using multi-omics approaches to evaluate cardiovascular diseases, indicating potential for this study's methodology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed as coronary heart disease or with unexplained chest pain needed to undergo coronary angiography. * Healthy subjects undergoing routine physical examination in the physical examination department and willing to sign informed consent will be recruited as control subjects. Exclusion Criteria: * With malignant tumors, infectious diseases and advanced liver diseases. * Won't sign an inform consent.
Where this trial is running
Jinan, Shandong
- Shandong First Medical University — Jinan, Shandong, China (RECRUITING)
Study contacts
- Study coordinator: Rong Huang, Dr.
- Email: huangrong9277@163.com
- Phone: 18854125717
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Heart Disease, Myocardial Infarction